Group by Gene: CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Chemotherapy DNA Tyrosine Kinase Inhibitors Epigenetics Other PARP Inhibitors | nivolumab | PD1 inhibitor pembrolizumab | PD1 inhibitor | DNA synthesis inhibitor gemcitabine | cisplatin | PD1 inhibitor, CTLA4 inhibitor nivolumab + ipilimumab | Tubulin polymerization promoter carboplatin | VEGF-A inhibitor bevacizumab | Tubulin polymerization promoter, Thymidylate synthase inhibitor carboplatin + raltitrexed | Tubulin polymerization inhibitor vinorelbine tartrate | VEGFR-2 inhibitor ramucirumab | TEAD1 inhibitor IK-930 | PD1 inhibitor, PARP inhibitor niraparib + dostarlimab-gxly | PRMT5 inhibitor MRTX1719 | Wilms tumor 1 inhibitor, PD1 inhibitor nivolumab + galinpepimut-S | ALK inhibitor crizotinib | alectinib | T-cell stimulant, Mesothelin inhibitor TC-210 | THF dehydrogenase inhibitor, Thymidylate synthase inhibitor pemetrexed | THF dehydrogenase inhibitor, Tubulin polymerization promoter, Thymidylate synthase inhibitor carboplatin + pemetrexed | THF dehydrogenase inhibitor, DNA synthesis inhibitor, Thymidylate synthase inhibitor cisplatin + pemetrexed | Chemotherapy GC | PD-L1 inhibitor PD-L1 inhibitor | THF dehydrogenase inhibitor, Arginine depleter, DNA synthesis inhibitor, Thymidylate synthase inhibitor cisplatin + pemetrexed + pegargiminase |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | ||||||||||||||||||||||||
NF2 deletion | ||||||||||||||||||||||||
BAP1 mutation | ||||||||||||||||||||||||
PD-L1 expression | ||||||||||||||||||||||||
BAP1 deletion | ||||||||||||||||||||||||
PD-L1 overexpression | ||||||||||||||||||||||||
PD-L1 underexpression | ||||||||||||||||||||||||
RRM1 expression | ||||||||||||||||||||||||
MSLN overexpression | ||||||||||||||||||||||||
ASS1 mutation | ||||||||||||||||||||||||
MTAP deletion + PIK3CA mutation | ||||||||||||||||||||||||
BRCA2 mutation | ||||||||||||||||||||||||
ERCC1 expression | ||||||||||||||||||||||||
CD74-ROS1 fusion | ||||||||||||||||||||||||
MTAP deletion + CDKN2A deletion + CDKN2B deletion + BAP1 deletion | ||||||||||||||||||||||||
WT1 expression | ||||||||||||||||||||||||
TMB-L | ||||||||||||||||||||||||
EML4-ALK I1171N + EML4-ALK L1196M |